International Journal of Radiation Oncology * Biology * Physics
Volume 80, Issue 1 , Pages 176-184 , 1 May 2011

Prognostic Value of Early [18F]Fluoroethyltyrosine Positron Emission Tomography After Radiochemotherapy in Glioblastoma Multiforme

  • Marc D. Piroth, M.D.

      Affiliations

    • Department of Radiation Oncology, RWTH Aachen University Hospital, Aachen, Germany
    • Juelich-Aachen Research Alliance, Section JARA-Brain, Jülich, Germany
    • Corresponding Author InformationReprint requests to: Marc D. Piroth, M.D., Department of Radiation Oncology, RWTH Aachen University Hospital, Pauwelsstraße 30, D-52074 Aachen, Germany. Tel: (+49) 0241-8035274; Fax: (+49) 0241-8082543
    • ,
  • Michael Pinkawa, M.D.

      Affiliations

    • Department of Radiation Oncology, RWTH Aachen University Hospital, Aachen, Germany
    • Juelich-Aachen Research Alliance, Section JARA-Brain, Jülich, Germany
    • ,
  • Richard Holy, M.D.

      Affiliations

    • Department of Radiation Oncology, RWTH Aachen University Hospital, Aachen, Germany
    • Juelich-Aachen Research Alliance, Section JARA-Brain, Jülich, Germany
    • ,
  • Jens Klotz, M.D.

      Affiliations

    • Department of Radiation Oncology, RWTH Aachen University Hospital, Aachen, Germany
    • Juelich-Aachen Research Alliance, Section JARA-Brain, Jülich, Germany
    • ,
  • Sandra Nussen, M.D.

      Affiliations

    • Department of Radiation Oncology, RWTH Aachen University Hospital, Aachen, Germany
    • Juelich-Aachen Research Alliance, Section JARA-Brain, Jülich, Germany
    • ,
  • Gabriele Stoffels, M.D.

      Affiliations

    • Institute of Neuroscience and Medicine, Research Center Jülich, Jülich, Germany
    • Juelich-Aachen Research Alliance, Section JARA-Brain, Jülich, Germany
    • ,
  • Heinz H. Coenen, Ph.D.

      Affiliations

    • Institute of Neuroscience and Medicine, Research Center Jülich, Jülich, Germany
    • Juelich-Aachen Research Alliance, Section JARA-Brain, Jülich, Germany
    • ,
  • Hans J. Kaiser, Ph.D.

      Affiliations

    • Department of Nuclear Medicine, RWTH Aachen University Hospital, Aachen, Germany
    • ,
  • Karl J. Langen, M.D.

      Affiliations

    • Institute of Neuroscience and Medicine, Research Center Jülich, Jülich, Germany
    • Juelich-Aachen Research Alliance, Section JARA-Brain, Jülich, Germany
    • ,
  • Michael J. Eble, M.D.

      Affiliations

    • Department of Radiation Oncology, RWTH Aachen University Hospital, Aachen, Germany
    • Juelich-Aachen Research Alliance, Section JARA-Brain, Jülich, Germany

Received 15 December 2009 ,Revised 22 January 2010 ,Accepted 26 January 2010.

References 

  1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996
  2. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–466
  3. Stupp R, Hegi ME, Gilbert MR, et al. Chemoradiotherapy in malignant glioma: Standard of care and future directions. J Clin Oncol. 2007;25:4127–4136
  4. Cao Y, Tsien CI, Shen Z, et al. Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol. 2005;23:4127–4136
  5. Kumar AJ, Leeds NE, Fuller GN, et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy induced necrosis of the brain after treatment. Radiology. 2000;217:377–384
  6. Lustig RA, Seiferheld W, Berkey B, et al. Imaging response in malignant glioma, RTOG 90-06. Am J Clin Oncol. 2007;30:32–37
  7. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008;26:2192–2197
  8. Brandsma D, Stalpers L, Taal W, et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9:453–461
  9. Chamberlain MC, Glantz MJ, Chalmers L, et al. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol. 2007;82:81–83
  10. Yang I, Aghi MK. New advances that enable identification of glioblastoma recurrence. Nat Rev Clin Oncol. 2009;6:648–657
  11. Singhal T, Narayanan TK, Jain V, et al. 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol. 2008;10:1–18
  12. Hamacher K, Coenen HH. Efficient routine production of the 18F-labelled amino acid O-2-18F fluoroethyl-L-tyrosine. Appl Radiat Isot. 2002;57:853–856
  13. Langen KJ, Hamacher K, Weckesser M, et al. O-(2-[18F]fluoroethyl)-L-tyrosine: Uptake mechanisms and clinical applications. Nucl Med Biol. 2006;33:287–294
  14. Wester HJ, Herz M, Weber W, et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med. 1999;40:205–212
  15. Floeth FW, Pauleit D, Wittsack HJ, et al. Multimodal metabolic imaging of cerebral gliomas: Positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. J Neurosurg. 2005;102:318–327
  16. Pauleit D, Floeth F, Hamacher K, et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain. 2005;128:678–687
  17. Popperl G, Gotz C, Rachinger W, et al. Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging. 2004;31:1464–1470
  18. Rachinger W, Goetz C, Popperl G, et al. Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery. 2005;57:505–511
  19. Floeth FW, Pauleit D, Sabel M, et al. Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med. 2007;48:519–527
  20. Popperl G, Goldbrunner R, Gildehaus FJ, et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging. 2005;32:1018–1025
  21. Popperl G, Gotz C, Rachinger W, et al. Serial O-(2-[(18)F]fluoroethyl)-L-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Imaging. 2006;33:792–800
  22. Wyss M, Hofer S, Bruehlmeier M, et al. Early metabolic responses in temozolomide treated low-grade glioma patients. J Neurooncol. 2009;95:87–93
  23. Curran WJ, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85:704–710
  24. Roesch P, Netsch T, McNutt T, et al. Syntegra: Automated image registration algorithms. Philips White Paper. 2003;
  25. Piroth MD, Pinkawa M, Holy R, et al. Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme: A dosimetric comparison. Radiat Oncol. 2009;4:57
  26. Weckesser M, Langen KJ, Rickert CH, et al. O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging. 2005;32:422–429
  27. Prescribing, recording and reporting photon beam therapy. Journal of the International Commission on Radiation Units and Measurements. 1993;
  28. Prescribing, recording and reporting photon beam therapy (Supplement to ICRU 50 Report). Journal of the International Commission on Radiation Units and Measurements. 1999;
  29. Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol. 2002;20:1635–1642
  30. Macdonald DR, Cascino TL, Schold SC, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277–1280
  31. Langen KJ, Roosen N, Coenen HH, et al. Brain and brain tumor uptake of L-3-[123I]iodo-alpha-methyl tyrosine: competition with natural L amino acids. J Nucl Med. 1991;32:1225–1229
  32. Ullrich RT, Kracht L, Brunn A, et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. J Nucl Med. 2009;50:1962–1968
  33. Galldiks N, Kracht LW, Burghaus L, et al. Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging. 2006;33:516–524
  34. Jacobs AH, Thomas A, Kracht LW, et al. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med. 2005;46:1948–1958
  35. Balmaceda C, Critchell D, Mao X, et al. Multisection 1H magnetic resonance spectroscopic imaging assessment of glioma response to chemotherapy. J Neurooncol. 2006;76:185–191
  36. Stadlbauer A, Prante O, Nimsky C, et al. Metabolic imaging of cerebral gliomas: Spatial correlation of changes in O-(2 18F-fluoroethyl)-L tyrosine PET and proton magnetic resonance spectroscopic imaging. J Nucl Med. 2008;49:721–729
  37. van den Bent MJ, Kros JM. Predictive and prognostic markers in neuro-oncology. J Neuropathol Exp Neurol. 2007;66:1074–1081
  38. Yip S, Iafrate AJ, Louis DN. Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers. J Neuropathol Exp Neurol. 2008;67:1–15
  39. Hegi ME, Liu L, Herman JG, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008;26:4189–4199
  40. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003

 Conflict of interest: none.

PII: S0360-3016(10)00229-4

doi: 10.1016/j.ijrobp.2010.01.055

International Journal of Radiation Oncology * Biology * Physics
Volume 80, Issue 1 , Pages 176-184 , 1 May 2011

Article Tools

* Image Usage & Resolution